| scholarly article | Q13442814 |
| P2093 | author name string | Jing Wang | |
| Li Pang | |||
| Liangan Chen | |||
| Yanwen Jiang | |||
| P2860 | cites work | Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow | Q24644116 |
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Cancer cells in transit: the vascular interactions of tumor cells | Q28243610 | ||
| Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis | Q33433688 | ||
| Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics | Q34018426 | ||
| Estimates of cancer incidence and mortality in Europe in 2008. | Q34095813 | ||
| Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents | Q35551162 | ||
| CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients | Q36694216 | ||
| Carcinoembryonic antigen (CEA) as tumor marker in lung cancer | Q37966302 | ||
| Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. | Q38482055 | ||
| CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. | Q41229334 | ||
| Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study | Q43033486 | ||
| Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer | Q44569104 | ||
| The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited | Q44814098 | ||
| Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib | Q45720480 | ||
| Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, an | Q46354099 | ||
| Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. | Q50689013 | ||
| Increased serum CA-125 levels in patients with lung cancer post thoracotomy. | Q51772806 | ||
| Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. | Q51799739 | ||
| Standard uptake value of positron emission tomography in clinical stage I lung cancer: clinical application and pathological correlation. | Q53182079 | ||
| Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China. | Q53205523 | ||
| An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions | Q73274552 | ||
| Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions | Q73405871 | ||
| Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis | Q77986128 | ||
| Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients | Q78448054 | ||
| Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC | Q80207047 | ||
| Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis | Q80439343 | ||
| Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer | Q81503268 | ||
| Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer | Q81724063 | ||
| The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer | Q82463045 | ||
| Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer | Q82791867 | ||
| Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response | Q83627391 | ||
| Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer | Q83786381 | ||
| Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients | Q83886953 | ||
| Biomarkers in the lung cancer diagnosis: a clinical perspective | Q84298465 | ||
| Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer | Q84652583 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 355-360 | |
| P577 | publication date | 2013-06-20 | |
| P1433 | published in | Experimental and Therapeutic Medicine | Q23979083 |
| P1476 | title | Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer | |
| P478 | volume | 6 |
| Q36631514 | A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy |
| Q87979575 | Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer |
| Q92326318 | Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer |
| Q38917304 | Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis |
| Q34235010 | Fibroblast phenotypes in different lung diseases |
| Q55517469 | Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. |
| Q50072119 | Utility of Multiple Increased Lung Cancer Tumor Markers in Treatment of Patients with Advanced Lung Adenocarcinoma |
Search more.